Benchmark starts Know Labs with a Speculative Buy, sees ‘first-mover advantage’

As previously reported, Benchmark initiated coverage of Know Labs with a Speculative Buy rating and $1 price target, citing the company’s “first-mover advantage” in non-invasive blood glucose monitoring. Know Labs aims to develop and commercialize the first non-invasive blood glucose monitor for diabetes management and unveiled its first-generation prototype in June 2023, with plans to launch an FDA-cleared, second-generation device in FY26, notes the analyst, who also believes the company’s proprietary Bio-RFID technology can be extended to other analytes of interest.